RxDoctor Payments Data

Scott Wagenberg, MD

Ophthalmology · Mayfield Hts, OHNPI 1821020447

Payments from drug & device makers

$1,109in general payments, 2019–2025

Across 67 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$256
  • AbbVie$223
  • Oyster Point Pharma, Inc.$175
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$104
  • Bausch & Lomb Americas Inc.$96
  • Alcon$82
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$1,09599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,109 in reported general payments places this provider in the 45th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$304,782
Medicare patients
1,209
Services billed
2,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj12$452,088
RestasisCyclosporine33$45,940
Prednisolone Acetate1,236$36,122
Fluorometholone431$31,769
CombiganBrimonidine Tartrate/Timolol83$31,174
XiidraLifitegrast25$23,403
Loteprednol Etabonate91$16,887
MoxifloxacinMoxifloxacin Hcl636$16,245
RhopressaNetarsudil Mesylate27$14,988
LumiganBimatoprost30$14,778
Latanoprost791$8,645
VyzultaLatanoprostene Bunod22$8,374
RocklatanNetarsudil Mesylat/Latanoprost16$7,611
Dexamethasone Sodium Phosphate153$5,895
Timolol Maleate293$5,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$28$452,08812 claims
AbbVieRestasis, Combigan, Lumigan$223$91,893146 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$96$31,77747 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$25$22,60043 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$104$16,88791 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Mayfield Hts

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →